Inflammation and the heart - prime time for new therapeutic approaches

François Roubille; Jean-Claude Tardif

doi:10.1517/14728214.2013.811487

Retour

Inflammation and the heart - prime time for new therapeutic approaches

Article de revue

Avec comité de lecture

Inflammation and the heart - prime time for new therapeutic approaches

François Roubille et Jean-Claude Tardif

Expert opinion on emerging drugs, Vol.18(3), pp.259-261

09/2013

DOI: https://doi.org/10.1517/14728214.2013.811487

PMID: 23790157

Résumé

Introduction: Atherosclerosis remains one of the main causes of cardiovascular disease. Areas covered: A brief overview of the work summarized by Berman et al. [Berman JP, Farkouh ME, Rosenson RS. Emerging anti-inflammatory drugs for atherosclerosis. Expert Opin Emerg Drugs 2013;18(2):193-205] on the development of anti-inflammatory drugs to tackle atherosclerosis is provided. Expert opinion: Indeed, recent data from clinical trials on anti-inflammatory drugs in coronary artery disease highlight the potential of such therapies.

Indicateurs

1 Consultations de la notice

Détails

Titre: Inflammation and the heart - prime time for new therapeutic approaches
Créateurs - sans rôle: François Roubille - Montreal Heart Institute, Université de Montréal
Jean-Claude Tardif - Montreal Heart Institute
Détails de publication: Expert opinion on emerging drugs, Vol.18(3), pp.259-261
Éditeur: Informa UK, Ltd
Nombre de pages: 3
Identifiants: 99158814409311
Unité académique: Physiologie et Médecine Expérimentale du coeur et des muscles - PhyMedExp
Langue: English
Type de ressource: Journal article